Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Sequencing Throughout Multiple Lines of Therapy in RR DTC

June 5th 2023

Before closing out their discussion on RR DTC management, panelists consider the advent of sequencing through multiple lines of therapy.

Optimizing Use of RET Inhibitors in Patients With RR DTC

May 29th 2023

Shared insight on the optimal use of RET inhibitor therapy in select patients with RET-rearranged radioiodine-refractory differentiated thyroid cancer.

Patient Scenario 3: Treating RR DTC With an Identified RET Fusion

May 29th 2023

Centering discussion on the final clinical scenario of RR DTC, Francis Worden, MD, highlights the management of a patient with an identified RET rearrangement.

Practical Considerations for Utilizing Second-Line Therapy in RR DTC

May 22nd 2023

Expert panelists provide comprehensive insight to the utilization of second-line therapy for patients with RR DTC, covering formulation, dosing, and adverse event management.

Clinical Data Behind Second-Line Therapy in RR DTC

May 22nd 2023

A broad view of clinical data behind use of cabozantinib therapy in the second-line setting of radioiodine-refractory differentiated thyroid cancer.

Patient Scenario 2: Second-Line Management of RR DTC With Cabozantinib

May 15th 2023

Moving on to a new clinical scenario, Lori Wirth, MD, reviews the second-line management of a patient who progresses on frontline systemic therapy.

RR DTC: Managing Adverse Events With Dose Reductions or Holds

May 15th 2023

Before closing out their discussion on the frontline treatment setting of RR DTC, panelists highlight dose reductions and planned treatment holidays to mitigate adverse events.

Quality of Life and Real-World Data in Patients With RR DTC

May 8th 2023

Expert perspectives on real world and quality of life data behind systemic therapy in patients with radioiodine-refractory differentiated thyroid cancer.

Overview of Available Treatment Options for RR DTC

May 8th 2023

Expert oncologists work together to review the treatment armamentarium for radioiodine-refractory differentiated thyroid cancer and identify factors that best inform selection of therapy.

Dr Burtness on the Exploration of VIC1911 and Adavosertib in HNSCC and Lung Cancer

May 3rd 2023

Barbara Burtness, MD, discusses preclinical data on the combination of VIC1911 and adavosertib in head and neck squamous cell carcinoma and lung cancer.

RR DTC: Active Surveillance vs Initiating Systemic Therapy

May 1st 2023

A brief review of when it is appropriate to initiate systemic therapy in patients with differentiated thyroid cancer as opposed to continuing active surveillance.

Defining Radioiodine-Refractory Differentiated Thyroid Cancer

May 1st 2023

Key opinion leaders in differentiated thyroid cancer take a moment to define radioiodine refractory disease and consider its implications in establishing a treatment pathway.

Petosemtamab Generates Early Clinical Activity and Tolerability in HNSCC

April 26th 2023

The bispecific antibody petosemtamab delivered responses with a manageable safety profile in patients with advanced head and neck squamous cell carcinoma.

Practical Considerations for Managing RR DTC With Systemic Therapy

April 24th 2023

Comprehensive insight on best practices in dose adjustment and adverse event management in patients receiving systemic therapy for RR DTC.

Patient Scenario 1: RR DTC Managed With Frontline Lenvatinib

April 24th 2023

Expert Marcia Brose, MD, PhD, reviews a patient case of radioiodine-refractory differentiated thyroid cancer (RR DTC) managed with frontline lenvatinib therapy.

Head and Neck, Breast cancer Research Highlights AACR Abstracts

April 20th 2023

University of Cincinnati Cancer Center researchers presented more than a dozen abstracts at the 2023 American Association for Cancer Research Annual Meeting, including findings that could advance treatments for head and neck and breast cancers.

Diagnosing DTC: Clinical Workup and Molecular Testing

April 17th 2023

Shared insight on best practices in diagnosing patients with differentiated thyroid cancer with a focus on histologic and molecular subtypes.

Overview on Differentiated Thyroid Cancer (DTC)

April 17th 2023

Opening discussion on the advent of differentiated thyroid cancer (DTC) and management, moderator Lori J. Wirth, MD, provides and overview of prevalence, subtypes, and prognosis.

FDA Grants Fast Track Designation to RRx-001 for Severe Oral Mucositis in Head and Neck Cancer

March 30th 2023

The FDA has granted a fast track designation to RRx-001 for the prevention and attenuation of severe oral mucositis associated with chemotherapy and radiation in patients with head and neck cancer.

PARP7 Inhibitor RBN-2397 Has Tolerable Safety Profile in Solid Tumors

March 17th 2023

RBN-2397, a PARP7 inhibitor, was found to be well tolerated and have preliminary antitumor activity as monotherapy in patients with advanced solid tumors, including head and neck squamous cell carcinoma, breast cancer, and squamous cell carcinoma of the lung.